Autoimmune pancreatitis - An ongoing challenge.

Published on Aug 14, 2020in Advances in Medical Sciences3.287
· DOI :10.1016/J.ADVMS.2020.07.002
Martin Blaho3
Estimated H-index: 3
(University of Ostrava),
Petr Dítě9
Estimated H-index: 9
(University of Ostrava)
+ 1 AuthorsBohuslav Kianička6
Estimated H-index: 6
(Masaryk University)
Sources
Abstract
Autoimmune pancreatitis is a rare form of chronic pancreatitis. The first descriptions of the disease date back to the 1990s. Etiology is multifactorial, with the use of genetic, environmental and complex immunological mechanisms. It is classified into two subtypes. Type 1 is part of a group of diseases called IgG4-related disease. Clinically is autoimmune pancreatitis manifested by icterus and abdominal discomfort. It can rarely present as acute pancreatitis. There is also a completely asymptomatic form of the disease. The diagnosis is based on abnormalities in histology, imaging methods, serology, the involvement of other organs in relation to IgG4-related disease, and a significant positive response to corticosteroid therapy. Differential diagnosis between the focal form of autoimmune pancreatitis and pancreatic cancer can be complicated, with endosonography playing an important role. In the treatment, we use corticosteroids and other immunosuppressants including biological therapy. Patients with the asymptomatic disease should also be treated to prevent late complications and exocrine and endocrine insufficiency. In addition to drug treatment, endoscopic and/or surgical treatment may be necessary. Even after recovery, the disease can relapse. The relationship between autoimmune pancreatitis and malignancies has not been clearly confirmed. The goal of this review is to provide a comprehensive look at autoimmune pancreatitis and translate latest scientific knowledge into clinical practice.
References70
Newest
#1Yuichi Takano (Showa University)H-Index: 6
#2Takahiro Kobayashi (Showa University)H-Index: 2
Last. Masatsugu Nagahama (Showa University)H-Index: 9
view all 11 authors...
A 66-year-old man who was on oral medication for type 2 diabetes experienced a rapid decline in glycemic control (increase in glycosylated hemoglobin level from 7.7 to 10.2% over 3 months). Abdominal ultrasonography revealed a 20-mm hypoechoic mass in the pancreatic tail. Serum tumor marker carbohydrate antigen 19–9 and DUPAN2 levels were within the respective normal ranges; serum IgG4 level was also normal at 21.8 mg/dL. Abdominal contrast computed tomography revealed a 26-mm tumor in the pancr...
Source
#1Ayana Okamoto (Kindai University)H-Index: 7
#2Tomohiro Watanabe (Kindai University)H-Index: 37
Last. Masatoshi Kudo (Kindai University)H-Index: 119
view all 5 authors...
: Autoimmune pancreatitis (AIP) is now considered a pancreatic manifestation of a newly proposed disease condition, IgG4-related disease (IgG4-RD). IgG4-RD is characterized by enhanced IgG4 antibody responses and multiple organ involvements. Recent epidemiological studies have addressed the incidence of cancer in patients with AIP and/or IgG4-RD. Surprisingly, a significant number of AIP patients were detected with cancer at or within one year of the diagnosis of AIP. Furthermore, around 50% of ...
Source
#1Matteo Tacelli (University of Palermo)H-Index: 7
#2Ciro Celsa (University of Palermo)H-Index: 10
Last. Calogero Cammà (University of Palermo)H-Index: 77
view all 9 authors...
Background & Aims Risk for relapse after induction of remission with steroid therapy has been studied extensively in patients with autoimmune pancreatitis (AIP), but findings have been equivocal. We performed a systematic review and meta-analysis to estimate the relapse rate of AIP after initial remission after steroid treatment and to identify factors associated with relapse. Methods Three reviewers searched MEDLINE, SCOPUS, and EMBASE until July 2018 to identify studies on rate of relapse of A...
Source
#1Sawako KurumaH-Index: 17
#2Terumi KamisawaH-Index: 77
Last. Taku TabataH-Index: 19
view all 7 authors...
Abstract Purpose To clarify the clinical characteristics of autoimmune pancreatitis (AIP) in immunoglobulin (Ig)G4-related kidney disease (IgG4-RKD). Patients and methods A total of 92 patients with AIP were divided into an IgG4-RKD-positive group (RKD-P group, n = 13) and an IgG4-RKD-negative group (RKD-N group, n = 79) on the basis of the diagnostic criteria for IgG4-RKD. Clinical characteristics, including: age; sex; the presence of extrapancreatic lesions other than renal lesions, proteinuri...
Source
#1Hsi-Chang Shih (NTU: National Taiwan University)H-Index: 1
#2Ming-Chu Chang (NTU: National Taiwan University)H-Index: 25
Last. Yu-Ting Chang (NTU: National Taiwan University)H-Index: 25
view all 8 authors...
Misdiagnosis of autoimmune pancreatitis (AIP) as pancreatic cancer (PDAC) or vice versa can cause dismal patents’ outcomes. Changes in IgG glycosylation are associated with cancers and autoimmune diseases. This study investigated the IgG glycosylation profiles as diagnostic and prognostic biomarkers in PDAC and AIP. Serum IgG-glycosylation profiles from 86 AIP patients, 115 PDAC patients, and 57 controls were analyzed using liquid chromatography–electrospray ionization mass spectrometry. Classif...
Source
#1Petr DiteH-Index: 17
#2Ivo NovotnyH-Index: 2
Last. Lumir Kunovsky (Masaryk University)H-Index: 6
view all 10 authors...
Background: Diagnosis of pancreatic cancer (PC) in early stages is still challenging for gastroenterologists. The early detection of cancer is one of the utmost importance for the successful therapy of this malignancy. An accurate differential diagnosis of focal pancreatic lesions plays also an important role, whether it is differential diagnosis of chronic pancreatitis from PC or autoimmune pancreatitis (AIP) from PC. Raised serum immunoglobulin G4 (IgG4) levels to twice the normal value are co...
Source
#1K.F. Patrick Tsang (Freeman Hospital)H-Index: 1
#2W. Kofi Oppong (Freeman Hospital)H-Index: 1
Last. K. Manu Nayar (Freeman Hospital)H-Index: 1
view all 5 authors...
Abstract Background/Objectives: Serum IgG4 level is used as a diagnostic criterion for immunoglobulin G4-related disease (IgG4-RD) but whether it predicts disease progression is unclear. Aim of the study was to investigate if serum IgG4 level at the time of diagnosis correlates with disease outcome. Methods Patients with a definitive diagnosis of IgG4-RD were included in this study. They were divided into two groups – Group 1 : Elevated serum IgG4 at diagnosis and Group 2: Normal serum IgG4 at d...
Source
#1Tomohiro Watanabe (Kindai University)H-Index: 37
#2Kosuke Minaga (Kindai University)H-Index: 20
Last. Warren Strober (NIH: National Institutes of Health)H-Index: 130
view all 5 authors...
Autoimmune pancreatitis (AIP) is a pancreatic manifestation of a recently defined disease form known as IgG4-related disease (AIP/IgG4-RD). AIP/IgG4-RD is characterized by elevated systemic IgG4 antibody concentrations and lesional tissues infiltrated by IgG4-expressing plasmacytes. In addition, recent studies have revealed that, in common with other autoimmune diseases, such as systemic lupus erythematosus (SLE) and psoriasis, AIP/IgG4-RD is associated with increased type I IFN (IFN-I) producti...
Source
#1Nima Hafezi-Nejad (Johns Hopkins University)H-Index: 50
#2Vikesh K. Singh (Johns Hopkins University)H-Index: 49
Last. Atif Zaheer (Johns Hopkins University)H-Index: 22
view all 5 authors...
: Autoimmune pancreatitis (AIP) is characterized by autoimmune inflammatory destruction of the pancreatic tissue. Imaging plays an essential role in the diagnosis. AIP type 1 is the pancreatic manifestation of immunoglobulin G4 (IgG4)-related disease and is associated with IgG4-positive plasma cell infiltration and fibrosis of multiple organ systems. Type 2 is a related disease with pancreatic inflammation with or without concurrent inflammatory bowel disease. The authors demonstrate the imaging...
Source
#1Sunyoung Lee (UOU: University of Ulsan)H-Index: 19
#2Jin-Hee Kim (UOU: University of Ulsan)H-Index: 32
Last. Seung Soo Lee (UOU: University of Ulsan)H-Index: 32
view all 8 authors...
Objectives To intraindividually compare the diagnostic performance of CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis (AIP) from pancreatic ductal adenocarcinoma (PDA).
Source
Cited By3
Newest
Diagnostika vzacneho onemocněni autoimunitni pankreatitidou (AIP) je demonstrovana na připadu pacienta, který prosel řadou vysetřeni, jež nebyla schopna diagnozu benigniho charakteru jednoznacně prokazat. Nemoc je forma chronicke pankreatitidy, přicemž nejdůležitějsim a prvnim cilem vysetřeni je vylouceni maligniho onemocněni slinivky a žlucových cest. Zatimco zobrazovaci metody vedly k podezřeni na malignitu, opakovana histologicka vysetřeni ji nepotvrzovala. Pote, co jsme podle dostupných diag...
Source
Source
Ordinary chronic pancreatitis is a well-known risk factor for pancreatic cancer, whereas such an association with autoimmune pancreatitis (AIP) is widely debated. Due to the rarity of the latter disorder, there are few specific clinical and epidemiological studies investigating the relation between AIP and pancreatic cancer, which do not seem to support it. However, these studies are affected by several limitations and, therefore, a link between AIP (and, specifically, type 1 AIP) and pancreatic...
Source
#1Peter MacingaH-Index: 4
#2Jana JarošováH-Index: 1
Last. Tomas HuclH-Index: 17
view all 4 authors...
IgG4-related disease is a recently defined clinical entity that can manifest itself in any organ. The most common gastrointestinal manifestations are diseases of the pancreas (autoimmune pancreatitis type 1) and biliary tree (IgG4-associated cholangitis); involvement of liver parenchyma is uncommon and the affection of tubular organs is very rare. IgG4-related pancreatitis and cholangitis can mimic malignancies in their clinical presentation. Diagnosis is often difficult and requires careful eva...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.